In pilot clinical studies using patient serum samples assayed by surface plasmon resonance (SPR), SubB2M detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers.
“SubB2M is potentially one of the most exciting breakthroughs in cancer diagnostics that I have seen in 40 years of medical research."
Not much $ but the news will put it back on the buy side and watch this space lists.
In pilot clinical studies using patient serum samples assayed by...
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $59.09M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 57.0¢ | 55.0¢ | $34.29K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 54.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 55287 | 2 |
View Market Depth
| Last trade - 14.18pm 01/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |